805250-31-1

Usage

Uses

Used in Pharmaceutical Development:
[1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI) is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block in the development of new drugs.
Used in Agrochemical Production:
In the agrochemical industry, [1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI) is used as a key component in the formulation of pesticides and other agrochemicals. Its chemical properties allow it to be incorporated into effective and targeted products for agricultural use.
Used in Polymer Production:
[1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI) is used as a monomer or a modifier in the production of polymers. Its aromatic nature and functional groups contribute to the properties of the resulting polymers, making it a useful component in the synthesis of various types of plastics and materials.

Upstream product

• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 87199-16-4 3-Formylphenylboronic acid 

Downstream Products

• 805250-48-0 4'-(benzyloxy)-2',6'-dimethylbiphenyl-3-carbaldehyde 
• 1359669-17-2 (5-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2-oxo-2,3-dihydro-1H-indol-1-yl)acetic acid 
• 1359669-13-8 (5-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-1,3-dihydro-2-benzofuran-1-yl)acetic acid 
• 1359669-11-6 (6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid 
• 1359669-08-1 6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 1359669-06-9 (5-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1H-indene-2-yl)acetic acid 
• 1359669-04-7 5-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1H-indene-2-carboxylic acid 
• 805249-10-9 (6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetic acid 
• 805249-08-5 (6-{[4'-(benzyloxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetic acid 
• 805250-49-1 [4'-(benzyloxy)-2',6'-dimethylbiphenyl-3-yl]methanol 
• 1359669-95-6 ethyl (5-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2-oxo-2,3-dihydro1H-indol-1-yl)acetate 
• 1359669-90-1 tert-butyl (5-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-1,3-dihydro-2-benzofuran-1-yl)acetate 
• 1359669-88-7 methyl (6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-1,2,3,4-tetrahydronaphthalen-2-yl)acetate 
• 1359669-86-5 ethyl 6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-1,2,3,4-tetrahydronaphthalene-2-carboxylate 

Relevant academic research and scientific papers

Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents

The cardiovascular complications were highly prevalent in type 2 diabetes mellitus (T2DM), even at the early stage of T2DM or the state of intensive glycemic control. Thus, there is an urgent need for the intervention of cardiovascular complications in T2DM. Herein, the new hybrids of FFA1 agonist and NO donor were design to obtain dual effects of anti-hyperglycemic and anti-thrombosis. As expected, the induced-fit docking study suggested that it is feasible for our design strategy to hybrid NO donor with compound 1. These hybrids exhibited moderate FFA1 agonistic activities and anti-platelet aggregation activities, and their anti-platelet effects mediated by NO were also confirmed in the presence of NO scavenger. Moreover, compound 3 revealed significantly hypoglycemic effect and even stronger than that of TAK-875 during an oral glucose tolerance test in mice. Potent and multifunctional hybrid, such as compound 3, is expected as a potential candidate with additional cardiovascular benefits for the treatment of T2DM.

SULFINIC ACID COMPOUNDS AS FREE FATTY ACID RECEPTOR AGONISTS

The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions including these compounds for the treatment of metabolic disorders including, for example, diabetes, obesity, metabolic syndrome, fatty liver disease, and bone disorders.

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Based on an old phenoxyacetic acid scaffold, CPU014 (compound 14) has been identified as a superior agonist by comprehensive exploration of structure-activity relationship. In vitro toxicity study suggested that CPU014 has lower risk of hepatotoxicity than TAK-875. During acute toxicity study (5–500 mg/kg), a favorable therapeutic window of CPU014 was observed by evaluation of plasma profiles and liver slices. Moreover, CPU014 promotes insulin secretion in a glucose-dependent manner, while no GLP-1 secretion has been enhanced. Other than good pharmacokinetic properties, CPU014 significantly improved glucose tolerance both in normal and diabetic models without the risk of hypoglycemia. These subversive findings provided a safer candidate CPU014, which is currently in preclinical study to assess its potential for the treatment of diabetes.

Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold

Based on a previously reported phenoxyacetic acid scaffold, compound 7 (HWL-088) has been identified as a superior free fatty acid receptor 1 (FFA1) agonist by comprehensive structure-activity relationship study. Our results indicated that the introduction of ortho-fluoro greatly increased the activity of phenoxyacetic acid series, and the unique structure-activity relationship in biphenyl moiety is different from previously reported FFA1 agonists. Moreover, the modeling study was also performed to better understand the binding mode of present series. Compound 7 significantly improved glucose tolerance both in normal and diabetic models, and even exerted greater potential on glucose control than that of TAK-875. These findings provided a novel candidate HWL-088, which is currently in preclinical study to evaluate its potential for the treatment of diabetes.

Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1

Free fatty acid 1 (FFA1/GPR40) has attracted extensive attention as a novel target for the treatment of type 2 diabetes for its role in the enhancement of insulin secretion with glucose dependency. Aiming to develop novel potent FFA1 agonists, a new series of phenylpropionic acid derivatives were designed and synthesized on the basis of the modification of chemical cement of TAK-875, AMG-837, and LY2881835. Among them, most promising compounds 7, 14, and 15 were obtained with EC50 values of 82, 79, and 88?nM, exhibiting a powerful agonistic activity compared to TAK-875 (95.1?nM). During Oral glucose tolerance test in normal mice, compound 7, 14, and 15 had significant glucose-lowering effect at the dose of 50?mg/kg. Furthermore, compound 15 (50?mg/kg) also significantly improved in glucose tolerance in type 2 diabetic mice. Herein, we reported the discovery and optimization of a series of potent FFA1 agonists. The discovery supported further exploration surrounding this scaffold.

4-diphenylcarboxylic acid compound and preparing method and application thereof

The invention relates to a 4-diphenylcarboxylic acid compound and a preparing method and application thereof, and belongs to the field of medicines. The 4-diphenylcarboxylic acid compound is shown inthe formula I. The 4-diphenylcarboxylic acid compound ex

A novel phenoxyacetic acid derivatives, their preparation and their use as medicaments (by machine translation)

The invention relates to a compound of general formula (I) indicated by the model phenoxyacetic acid derivatives, preparation method thereof and containing the pharmaceutical composition as a preparation for the treatment of diabetes and metabolic syndrome in pharmaceutical use. The phenoxyacetic acid derivatives have an excellent in vivo hypoglycemic activity, it can be used for preventing or treating diabetes. (by machine translation)

(S) - 2 - (2,3-dihydrobenzo-furan-3-yl) acetic acid derivatives, its preparation process and its use in medicine

The invention relates to an (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative, a preparation method of the derivative, a medicine composition containing the derivative and the application of the derivative serving as a therapeutic agent, particularly GPR40/FFA1, and particularly provides the (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative shown in a general formula (I), and pharmaceutically acceptable salts of the derivative or a prodrug of the derivative. The compound is an agonist of a GPR40/FFA1 receptor and has a good preventive and therapeutic effect on lots of GPR40-mediated diseases, especially diabetes mellitus. The invention also provides a preparation method of the compound.

TAK-875 analog, and preparation method and application thereof

The invention relates to a TAK-875 analog, and a preparation method and an application thereof, concretely relates to a compound with a structure represented by general formula (I), and various optical isomers, pharmaceutically acceptable salts, solvates

CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS

The invention relates to compounds for increasing GPR40 recetpor activity and application thereof. These compounds include of a compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, isomers thereof, or produgs of the compou